Understanding the Development of NCCN Guidelines for High Risk Breast, Ovarian, Pancreatic & Prostate Cancer

Wednesday, April 2, 2025

4:00am PDT

1 hour

C.E.U.: 1 Category 1 Contact Hour

P.A.C.E.: 1 Unit

In this presentation, Leigha Senter, a current member of the NCCN Guideline Committee for Genetic/Familial High-Risk Assessment for Breast, Ovarian, Pancreatic, and Prostate cancers will review the process by which these guidelines are written and reviewed. Attendees will learn how evidence is categorized and considered and how varied feedback is considered.

Level of Instruction: Intermediate

Explore Our Tests Patient Billing Billing CARE

Rachel Bluebond

Oncology Genomic Science Liaison

Rachel Bluebond joined Ambry in 2020 as the Oncology Genomic Science Liaison for the South Central Region.  In her current role she serves as a clinical liaison for the field team to educate health care providers and key opinion leaders on genetic testing and genomic medicine. Rachel previously worked as a clinical oncology genetic counselor […]

Rachel Bluebond joined Ambry in 2020 as the Oncology Genomic Science Liaison for the South-Central Region.  In her current role she serves as a clinical liaison for the field team to educate health care providers and key opinion leaders on genetic testing and genomic medicine. Rachel previously worked as a clinical oncology genetic counselor at the University of Texas MD Anderson Cancer Center in Houston, Texas for 7 years and has worked with PWNHealth providing telehealth genetic counseling for 4 years. Rachel has been involved in graduate education at the UT MD Anderson UT Houston School of Biomedical Sciences. She is a member of the National Society of Genetic Counselors and the chair of the Billing Workgroup of the Access and Service Delivery Committee. Rachel received her Master of Medical Science degree in Human Genetics and Genetic Counseling from Emory University and is certified by the American Board of Genetic Counseling.